CCNT1 Antibody
| Code | Size | Price |
|---|
| PSI-7223-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7223-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
CCNT1 Antibody: CCNT, CYCT1, HIVE1, Cyclin-T1, CycT1
Application Note:
CCNT1 antibody can be used for detection of CCNT1 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
CCNT1 Antibody: Cyclins function as regulators of CDK kinases and exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. The cyclin-T1 protein (CCNT1) belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. CCNT1 tightly associates with CDK9 kinase, and was found to be a major subunit of the transcription elongation factor p-TEFb. The kinase complex containing CCNT1 and the elongation factor can interact with, and act as a cofactor of human immunodeficiency virus type 1 (HIV-1) Tat protein, and was shown to be both necessary and sufficient for full activation of viral transcription. CCNT1 and its kinase partner were also found to be involved in the phosphorylation and regulation of the carboxy-terminal domain (CTD) of the largest RNA polymerase II subunit.
Background References:
- Uhlmann F, Bouchoux C, and Lopez-Aviles S. A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited. Philos. Trans. R. Soc. Lond. B. biol. Sci. 2011; 366:3572-83.
- Wei P, Garber ME, Fang SM, et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92:451-62.
- Mancebo HS, Lee G, Flygare J, et al. P-TEFb kinase is require for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 1997 ; 11 :2633-44.
- Majello B and Napolitano G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front. Biosci. 2001; 6:D1358-68.
Buffer:
CCNT1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Rabbit polyclonal CCNT1 antibody was raised against an 18 amino acid peptide near the carboxy terminus of human CCNT1.
The immunogen is located within the last 50 amino acids of CCNT1.
The immunogen is located within the last 50 amino acids of CCNT1.
NCBI Gene ID #:
904
NCBI Official Name:
cyclin T1
NCBI Official Symbol:
CCNT1
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 80 kDa
Protein Accession #:
NP_001231
Protein GI Number:
17978466
Purification:
CCNT1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
O60563
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | CCNT1 Peptide | PSI-7223P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|